Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.
He WenjingYuanyuan ShaoYi YuWei HuangGuoliang FengJunhe LiPublished in: The Prostate (2020)
Our study demonstrated that exendin-4 alleviated resistance to enzalutamide, and suggested that exendin-4 combined with enzalutamide may be a more efficacious treatment for patients with advanced prostate cancer.